Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
Showing 101 - 120 of 138
-
-
For The Babies Of The Opioid Crisis, The Best Care May Be Mom’s Recovery
Research is just beginning on infants born with neonatal abstinence syndrome, and doctors are optimistic that normal development is possible. Monitoring the families and making sure parents are treated for addiction is key.
-
Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
-
How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
-
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
By Sarah Jane Tribble and Liz Szabo -
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
-
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
-
Patients With Rare Diseases And Congress Square Off Over Orphan Drug Tax Credits
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
-
Heated And Deep-Pocketed Battle Erupts Over 340B Drug Discount Program
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
-
Medicare Seeks Comment On Ways To Cut Costs Of Part D Drugs
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
-
Pressure Builds To Cut Medicare Patients In On Prescription Deals
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
-
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
-
Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers — middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
-
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
-
The Orphan Drug Machine
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
-
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
-
Congress Squares Off Over Drug Pricing And A Controversial Drug Discount Program
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.
-
Many COPD Patients Struggle To Pay For Each Medicinal Breath
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: